Drug intelligence / Profile preview

AGU probiotics

Development stage: Unknown
Lead developer: AGU Baby
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

AGU probiotics is a probiotic dietary supplement developed by AGU Baby, specifically formulated as oral drops for infants. The primary active ingredient is the well-characterized probiotic strain *Bifidobacterium animalis* subsp. *lactis* BB-12. The product is designed to support the establishment and maintenance of a healthy gut microbiome in neonates and infants, particularly those whose natural colonization may be disrupted by factors such as Cesarean delivery or antibiotic exposure. AGU probiotics has been evaluated in clinical research (e.g., NCT04548583) to assess its impact on the composition, diversity, and development of the infant intestinal microbiota.

Brand names: AGU Probiotic
Other names: AGU Probiotic drops

Beyond the preview

Go deeper on AGU probiotics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGU probiotics.

Explore the full profile